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SUMMARY
FANCM remodels branched DNA structures and plays essential roles in the cellular response to
DNA replication stress. Here we show that FANCM forms a conserved DNA remodeling complex
with a histone-fold heterodimer, MHF. We find that MHF stimulates DNA binding and replication
fork remodeling by FANCM. In the cell, FANCM and MHF are rapidly recruited to forks stalled by
DNA interstrand crosslinks, and both are required for cellular resistance to such lesions. In
vertebrates, FANCM-MHF associates with the Fanconi anemia (FA) core complex, promotes
FANCD2 monoubiquitination in response to DNA damage, and suppresses sister-chromatid
exchanges. Yeast orthologs of these proteins function together to resist MMS-induced DNA damage
and promote gene conversion at blocked replication forks. Thus, FANCM-MHF is an essential DNA
remodeling complex that protects replication forks from yeast to human.
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INTRODUCTION
Fanconi anemia (FA) is a genetically heterogeneous syndrome characterized by genomic
instability, congenital abnormalities, bone marrow failure, and cancer predisposition. FA can
be caused by mutation in any of 13 different FANC genes. The hallmark of FA cells is their
hypersensitivity to drugs that induce DNA interstrand crosslinks (ICLs), which prevent
separation of the complementary strands of DNA and completely block replication and other
essential processes. Increasing evidence suggests that FANC proteins act both as signal
transducers and as DNA processing molecules in a DNA damage response network, the FA-
BRCA network, which is essential to repair or bypass ICLs during DNA replication (Thompson
and Hinz, 2009; Wang, 2007).
The FANC proteins can be divided into three groups, based on their participation at different
stages of the FA-BRCA network (Wang, 2007). Group I acts at the early stage of the pathway
and consists of eight FANC proteins, FANCA, FANCB, FANCC, FANCE, FANCF, FANCG,
FANCL, and FANCM. These proteins, together with FAAP100 and FAAP24, constitute the
FA core complex. The FA core complex has two main functions. First, it monoubiquitinates
group II FA proteins, FANCD2 and FANCI, in response to DNA damage or during the S phase
of the cell cycle; and second, it directly participates in DNA repair through a DNA remodeling
enzyme, FANCM (Xue et al., 2008). Group II FANC proteins include FANCD2 and FANCI,
which form the FANCI-FANCD2 complex. Once ubiquitinated, this complex associates with
chromatin and colocalizes with the Group III FANC proteins, FANCD1/BRCA2, FANCN/
PALB2 and FANCJ/BRIP1. The group III proteins all interact with BRCA1 and are thought
to mediate HR-dependent DNA repair.
FANC proteins and FAAPs usually have orthologs in vertebrates but not in yeast. A single
exception is FANCM, which not only has an ortholog in yeast, but also in archea (Wang,
2007). This implies that the DNA remodeling function of FANCM is important enough to be
conserved through evolution. The yeast orthologs of FANCM, MPH1 in S. cerevisiae and Fml1
in S. pombe, possess a helicase motif and are capable of dissociating D-loops (an HR
intermediate) and suppressing chromosome crossover recombination induced by double-strand
breaks (Banerjee et al., 2008; Prakash et al., 2009; Sun et al., 2008). Fml1 can also stimulate
replication fork reversal in vitro, and promote gene conversion at stalled replication forks in
vivo (Sun et al., 2008).
Human FANCM contains an ATP-dependent branch-point translocase activity which promotes
migration of Holliday junctions, replication fork reversal, and dissociation of D-loops (Gari et
al., 2008a; Gari et al., 2008b; Xue et al., 2008). The ATP-dependent activity of FANCM is
required for cellular resistance to DNA crosslinking agents, but is dispensable for the
monoubiquitination function of the FA core complex (Rosado et al., 2009; Singh et al., 2009;
Xue et al., 2008). FANCM binds specifically and with high affinity to Holliday junctions and
replication forks (Gari et al., 2008b; Xue et al., 2008), and this DNA binding activity seems to
be required for efficient monoubiquitination of FANCD2 (Xue et al., 2008). FANCM has a
DNA-binding partner, FAAP24, which can target FANCM to single-strand DNA, an
intermediate of both DNA replication and repair (Ciccia et al., 2007). The FANCM/FAAP24
dimer is needed to tolerate damage induced by UV and camptothecin, and for suppression of
crossover recombination (Rosado et al., 2009; Singh et al., 2009).
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Here, we describe a histone-fold protein complex, named MHF, as a new component of the
FA core complex and an essential co-factor of FANCM. We present evidence that MHF and
FANCM form a conserved DNA remodeling complex that maintains genomic stability from
yeast to human.
RESULTS
Identification of MHF1 and MHF2 as integral components of the FA core complex
To search for additional components of the FA core complex, we fractionated HeLa nuclear
extract by gel-filtration chromatography, collected peak fractions containing FANCM (peak 1
in Figure 1A), and immunoprecipitated with a FANCM antibody. Silver-staining (Figure 1B),
mass spectrometry analyses (data not shown), and immunoblotting (Figure 1C) revealed the
presence of all known components of the FA core complex (FANC-A,-B, -C, -E, -F, -G -L, -
M, FAAP100 and FAAP24) in the FANCM immunoprecipitate. Most of the Bloom syndrome
complex components (BLM, TOPIIIα, RMI1/BLAP75, RPA70, and RPA32) were also
identified by mass spectrometry (data not shown), supporting our previous findings that the
FA core and BLM complexes associate in a super-complex, BRAFT (Wang, 2007).
Silver-staining detected two polypeptides of about 16 and 10 kDa that were not previously
identified (Figure 1B). Mass spectrometry revealed the 16 kDa protein as CENP-S or APITD1
(gene accession ID: NP_954988) (Foltz et al., 2006; Krona et al., 2004), and the 10 kDa
polypeptide as a protein with accession ID of A8MT69 or CENP-X (Amano et al., 2009).
A8MT69 has a confusing name of STRA13, which refers to two distinct proteins: one is
A8MT69, and the other is an unrelated helix-loop-helix transcription factor. Of 56 published
articles on STRA13, only one is on A8MT69, which shows that deletion of the A8MT69
ortholog in fission yeast may result in sensitivity to several genotoxins (Deshpande et al.,
2009). To avoid the confusion, we renamed the 16 and 10 kDa polypeptides as MHF1 and
MHF2, respectively (for FANCM (or MPH1)-associated Histone Fold protein 1 or 2).
The following evidence indicates that MHF1 and MHF2 are components of the FA core
complex. First, immunoblotting showed that antibody against MHF1 or MHF2 recognized the
corresponding polypeptide in the immunoprecipitate obtained with either FANCM or FANCA
antibody (Figure 1C). Second, one peak of MHF1 or MHF2 on Superose 6 column is coincident
with that of FANCM, supporting the notion that they are present in the same FA core complex
(Figure 1A, peak 1). Third, reciprocal immunoprecipitation using a MHF1 antibody from the
pooled Superose fractions of peak 1 obtained the same set of polypeptides isolated by the
FANCM antibody, including components of both FA core and BLM complexes, as evidenced
by silver-staining (Figure 1D), mass spectrometry (data not shown), and immunoblotting
(Figure 1C). Finally, MHF2-associated polypeptides isolated by a Flag antibody from the
extract of HeLa cells stably expressing Flag-tagged MHF2 also contained MHF1, FANCM
and other FA core complex components (Figure 1E).
We noticed that MHF1 and MHF2 co-fractionate in two peaks on a Superose 6 column (Figure
1A). While peak 1 corresponds to the FA core complex of about 1 MDa, peak 2 corresponds
to a complex of much smaller size. When peak 2 fractions were immunoprecipitated with a
MHF1 antibody, only MHF1 and MHF2 were isolated (Figure 1F), as revealed by mass
spectrometry (data not shown), indicating that these two proteins could comprise a complex
distinct from the FA core complex. The two MHF proteins appear to be approximately
equimolar amounts on the silver-stained gel, suggesting that they are likely obligate partners.
Direct interaction between MHF1 and MHF2 was observed by mammalian two-hybrid
analyses (Figure S1).
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MHF1 and MHF2 are conserved from human to yeast and form a new histone-fold complex
Bioinformatics revealed that both MHF proteins contain a histone-fold, which can mediate
both protein-protein and protein-DNA interactions (Figure S2A and B) (Arents and
Moudrianakis, 1993). Proteins containing this motif often associate to form heterodimeric or
heterotetrameric complexes that bind to bent DNA. Our purification of MHF1 and MHF2 as
a stoichiometric complex from HeLa extract (Figure 1F) fits well with the bioinformatic
prediction that they form a histone-fold complex.
We co-expressed MHF1 with HIS-tagged MHF2 in E. coli, and purified the complex using
Talon metal affinity chromatography. Coomassie-staining revealed that the two proteins were
present in approximately equimolar amounts (Figure 2A, lane 3), indicating that they indeed
form a heterodimeric complex. We named this complex MHF.
MHF possesses DNA binding properties distinct from FANCM and FAAP24
Like other histone-fold complexes, MHF was found to bind double-strand DNA (dsDNA), but
not single-strand DNA (ssDNA) (Figure 2B, lanes 1-10). This activity requires the MHF
complex because individual MHF subunit lacked the activity.
MHF was also found to bind several structured DNAs containing different branch points
(Figure 2B, lanes 11-30). Notably, the affinity of MHF to these structures was either similar
or somewhat reduced compared to that of dsDNA of the same length (compare lanes 10, 15,
20, 25 and 30), indicating that MHF has no increased affinity for branched DNA, and its binding
may even be precluded by such structures. The binding of MHF to dsDNA was further
visualized by electron microscopy (Figure S3A and B). MHF appeared to form clusters which
result in compaction of DNA, suggesting self-association between MHF proteins.
The DNA binding characteristics of MHF differ from those of FANCM and FAAP24, which
specifically recognize branched and ssDNA, respectively (Ciccia et al., 2007; Gari et al.,
2008b; Xue et al., 2008). We propose that these proteins constitute a molecular machine that
binds cooperatively to different parts of a stalled replication fork: FANCM binds the branch
point, whereas MHF and FAAP24 associate with dsDNA and ssDNA regions, respectively
(see Discussion). Moreover, we have also shown that MHF can bind chromatin (Figure S3C)
and cooperate with histone octamers to assemble into nucleosome structures in vitro (Figure
S3D and E), which is consistent with MHF aiding FANCM association with DNA in vivo.
Furthermore, MHF can efficiently anneal complementary single-stranded DNAs (albeit not
when they are pre-bound by RPA) (Figure S3F and G), which could assist the catalysis of
branch point migration by FANCM.
MHF and FANCM co-evolved and form an independent complex
Bioinformatics analyses revealed that MHF1 and MHF2 orthologs are present in all eukaryotes,
including yeast (Figure S2C and D). This feature is shared by FANCM but not by other FANC
proteins or FAAPs, most of which have orthologs only in vertebrates (Wang, 2007). The data
suggest that FANCM, MHF1 and MHF2 may perform functions important to all eukaryotes
that favor their co-evolution.
The co-evolution of FANCM and the two MHF proteins implies that they may constitute a
complex that lacks other FANC proteins. To distinguish this complex from the FA core
complex in HeLa cells, we omitted the Superose 6 fractionation step that was used for
enrichment and purification of the FA core complex (Figure 1D). We performed
immunoprecipitation directly from HeLa extract with the same MHF1 antibody, and obtained
FANCM, MHF1 and MHF2 as the only three major polypeptides (Figure 3A). Other FANC
proteins can only be detected by immunoblotting due to their lower levels (data not shown).
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The data suggest that significant amounts of MHF and FANCM are present in a complex largely
free of other FANC proteins. We named this complex FANCM-MHF.
Majority of MHF and FANCM do not associate with the FA core complex
We quantitatively immunodepleted the FA core complex from HeLa extract with the FANCA
antibody, and found that less than 30% of FANCM, MHF, and FAAP24 were co-depleted
(Figure S4A), Similarly, depletion of FAAP24 or MHF from the extract co-depleted FANCA
by less than 25% (Figure S4B and C). These data suggest that majority of FANCM and its two
partners do not associate with the FA core complex. Conversely, immunodepletion of either
FAAP24 or MHF co-depleted FANCM by about 70% and 85% (Figure S4B and C), indicating
that most of FANCM in cells associates with either or both of its partners.
MHF and FAAP24 can form separate complexes with FANCM
We immunoprecipitated MHF from the FAAP24-depleted extract and obtained FANCM but
no FAAP24 (Figure S4B, lane 4), suggesting that MHF and FANCM can form a complex
without FAAP24. Similarly, we immunoprecipitated FAAP24 from the MHF-depleted extract
and obtained FANCM but no MHF (Figure S4C, lane 4), indicating FAAP24 and FANCM can
also form a complex without MHF. Together with the results in Figure 1 which showed that
FANCM and both partners co-IP, our data suggest that FANCM can associate with its partners
in a combinatorial manner to form distinct complexes: FANCM-MHF, FANCM-FAAP24, and
FANCM-MHF-FAAP24.
MHF interacts with FANCM and promotes its DNA binding activity
We mapped the MHF-interaction domain within FANCM to a region near the helicase domain
of FANCM (aa. 661-800) by IP-Western analyses of a series of FANCM deletion mutants
(Figures 3B and S4D). We have previously shown that both the full-length FANCM protein
and its N-terminal fragment (1-754 aa.) encompassing the helicase domain (FANCM754) have
high affinity for branched DNA structures, but not for dsDNA (Gari et al., 2008b; Xue et al.,
2008). The current findings that MHF interacts with both FANCM and dsDNA predict that
MHF may recruit FANCM to dsDNA. Consistent with this prediction, FANCM754 alone
exhibited little dsDNA binding activity (Figure 3C, lanes 2-4), while MHF and FANCM754
together displayed strong binding activity (see the supershifted band in Figure 3C, lanes 6 to
8 vs. 5).
FANCM and MHF bind DNA synergistically
The fact that FANCM and the two MHF proteins can form a complex raised a possibility that
they may bind DNA cooperatively. Indeed, not only did MHF enhance the DNA binding of
FANCM754, FANCM754 also stimulated the DNA binding activity of MHF (Figure 3C; the
unbound DNA was reduced in lane 6 compared to lane 5). Moreover, FANCM754 and MHF
bound DNA synergistically at low protein concentrations: while either protein alone showed
little binding activity, both proteins together displayed an activity much higher than the sum
of individuals (Figure 3C; less than 1% of dsDNA was shifted in lanes 10-13, whereas 50-90%
of DNA was shifted in lanes 14-16). This synergy was also observed for fork and Holliday
junction (HJ) substrates (Figure 3C, lanes 17 to 32).
We reconstituted the FANCM-MHF complex by co-expressing full-length recombinant
FANCM, MHF1 and MHF2 proteins in insect cells, and purified the trimeric complex (Figure
3D). Incubation of FANCM-MHF with synthetic replication forks led to formation of a defined
protein-DNA complex whose mobility was reduced compared to that of FANCM-fork
complex, suggesting that FANCM, MHF1 and MHF2 bind together to branched DNA
molecules (Figure 3E). Moreover, the FANCM-MHF complex had a stronger fork binding
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activity than FANCM alone (Figure 3E), providing further evidence that FANCM-MHF binds
DNA cooperatively.
MHF stimulates replication fork reversal activity of FANCM
FANCM exhibits an ATP-dependent replication fork reversal activity, which may stabilize
stalled forks and facilitate assembly of DNA damage signaling and repair complexes (Gari et
al., 2008a). We found that recombinant FANCM-MHF had a fork reversal activity stronger
than that of FANCM (Figure 3F, G and H). Both FANCM and FANCM-MHF catalyzed
reversal of a model replication fork into a four-way junction intermediate, and led to the
formation of a labeled linear DNA duplex, the end product of complete fork reversal (Figure
3G and H). At low protein concentrations, however, FANCM-MHF produced higher levels of
four-way junction intermediate (about 5 to 7 -fold) and linear regression product (about 2 to 3
-fold) than FANCM alone (Figure 3G and H). These data establish FANCM-MHF as a DNA
remodeling machine, and suggest that MHF is a crucial co-factor for FANCM in both binding
and ATP-dependent remodeling of DNA.
MHF is required for stability of FANCM and for activation of the FA pathway
We next examined whether MHF is required for FANCM function in vivo. SiRNA depletion
of either MHF1 or MHF2 in HeLa cells reduced the level of FANCM in whole cell lysates
(Figure 4A) and the chromatin fractions (Figure 4B), suggesting that MHF is required for
stability of FANCM and may also be important for chromatin association of FANCM.
Depletion of one MHF protein also reduced the protein level of the other (Figure 4A), providing
additional evidence that MHF1 and MHF2 are direct interacting partners and depend on each
other for stability.
HeLa cells depleted of either MHF protein displayed reduced levels of monoubiquitinated
FANCD2 and FANCI in response to DNA crosslinking drugs, mitomycin C (MMC) and
cisplatin (Figure 4C and D). The cells also exhibited hypersensitivity to these drugs (Figures
4E and S5A), and increased chromosomal breaks in response to MMC (Figure S5B). All these
phenotypes are characteristics for cells defective in FA core complex components, indicating
that MHF is important for normal functions of the core complex and the FA pathway.
We noticed that HeLa cells depleted of FANCM or MHF were sensitive to methyl
methanesulfonate (MMS), a DNA alkylating agent (Figure 4F). This feature has been found
in hamster cells mutated of FANCG (Tebbs et al., 2005), and in yeast FANCM (Banerjee et
al., 2008; Sun et al., 2008) and MHF mutants (see below), suggesting that some DNA repair
functions of FANCM-MHF are conserved in lower eukaryotes.
Cells depleted of MHF also exhibited sensitivity to camptothecin (CPT), a topoisomerase I
inhibitor (Figure 4G). This feature was observed in cells depleted of FANCM but not in those
lacking other components of the FA core complex (Rosado et al., 2009; Singh et al., 2009).
The results suggest that FANCM-MHF may have functions independent of the FA core
complex.
MHF and FANCM are rapidly recruited to DNA interstrand crosslinks (ICLs) that block
replication
Because cells depleted of FANCM or MHF are hypersensitive to drugs that induce ICLs, we
examined whether FANCM-MHF localizes at ICLs using two independent techniques. First,
we utilized laser-activated psoralen conjugates to generate ICLs within a localized region in
nucleus, and then visualize proteins recruited to this region by indirect immunofluorescence
(Thazhathveetil et al., 2007). Both FANCM and MHF1 were recruited to the ICLs within 15
min after photoactivation, in a subgroup of cells in random culture (about 15%) (Figure 5A
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and data not shown), while they were not recruited to DNA monoadducts generated by laser-
activated angelicin (Thazhathveetil et al., 2007). Co-staining with a cell cycle marker (NPAT)
revealed that the recruitment occurred only in S phase cells (Figure S6A, B, C, and data not
shown). When cells were synchronized in S phase, the recruitment was increased to
approximately 50% of the cell population (Figure S6D). The fact that the recruitment of
FANCM and MHF to ICLs occurs only during S phase provides in vivo evidence for FANCM-
MHF to remodel replication forks blocked by crosslinked DNA. Notably, the recruitment of
FANCM (but not γ-H2AX) was strongly diminished in cells depleted of either MHF1 or MHF2
(Figure 5B and C). This may be due to reduced stability (Figure 4A) and/or impaired targeting
of FANCM in the absence of MHF.
We also used eChIP, a chromatin-IP based method that detects proteins at a site-specific
psoralen ICL on an episomal plasmid transfected into cells (Figure 5D)(Shen et al., 2009). This
plasmid contains the replication origin of Epstein-bar virus (EBV), so that the plasmid without
the ICL can undergo replication unidirectionally in EBNA-293 cells that express the Epstein-
bar nuclear antigen 1 (EBNA). For the plasmid carrying the ICL (which was positioned 488
bp downstream of the replication origin), the replication fork is stalled by the crosslink, and
proteins accumulated at the stalled fork can be detected by ChIP-PCR using a primer set that
amplifies a DNA fragment near the crosslink. The same plasmid can be introduced into standard
293 cells that lack EBNA for detection of proteins recruited to ICL under non-replicating
conditions. We found that MHF1 was enriched about 5-fold at the ICL when the episomal
vector was allowed to replicate in EBNA-293 cells (Figure 5E). However, the enrichment was
reduced to less than 2-fold in the 293 cells that do not support vector replication. In comparison,
FAAP24 was enriched at the ICL under both replicating and non-replicating conditions (Figure
5E), in agreement with previous findings (Shen et al., 2009). These data are congruent with
the notion that MHF functions at the replication forks blocked by ICLs, most likely in the form
of the FANCM-MHF complex.
MHF and FANCM act in the same pathway for FANCD2 monoubiquitination and suppression
of sister-chromatid exchange (SCE)
We have screened FA patients for mutations in MHF1 and MHF2, but have failed to identify
such individuals (data not shown). To study the functions of MHF genetically, we inactivated
MHF1 in chicken DT40 cells (Figure S7A, B and C). Compared to wildtype cells, MHF1-/-
cells exhibited a lower level of FANCM and MHF2, a reduced level of monoubiquitinated
FANCD2 (Figure 6A, lanes 1-2), and a decreased number of FANCD2 nuclear foci (Figure
S7D and E). Introduction of human MHF1 into MHF1-/- cells restored FANCD2
monoubiquitination, and also resulted in over expression of FANCM (2-fold) and MHF2 (11-
fold) compared to wildtype cells (Figure 6A, lanes 1-3). These findings are consistent with
siRNA data from HeLa cells that MHF1 is required for normal FANCD2 monoubiquitination
and for stability of FANCM and MHF2.
We generated FANCM-/-/MHF1-/--double mutant cells (data not shown), and found that they
contained the levels of monoubiquitinated FANCD2 comparable to that of FANCM-/- cells in
the presence of MMC (Figure 6B). These results suggest that MHF and FANCM act in a
common pathway to promote efficient monoubiquitination of FANCD2.
DT40 cells inactivated of FANC genes exhibit higher levels of SCEs (Rosado et al., 2009).
The level of SCEs in MHF1-/- cells was about 3 to 4-fold higher than that of wildtype cells (9.7
vs. 2.5), and this elevated SCE level could be corrected by expression of human MHF1 (Figure
6C). The data suggest that MHF participates in suppression of SCEs in DT40 cells. The SCE
level in MHF1-/- cells is lower than that of FANCM-/- cells (9.7 vs. 18.3), suggesting that
without MHF, FANCM remains partially active in maintaining genome integrity (Figure 6C).
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The SCE level of FANCM-/-/MHF1-/- cells is comparable to that of FANCM-/- cells (17.9 vs.
18.3), indicating that MHF and FANCM act through the same pathway to suppress SCEs.
MHF1-/- DT40 cells lacked cellular sensitivity and chromosomal breakage in response to DNA
ICL drugs (data not shown), which are phenotypes of DT40 cells inactivated of FANC genes.
These results differ from those of siRNA studies in HeLa cells. Possibly, the balance between
DNA repair and cell death pathways may be different between these cells.
The DNA binding activity of MHF is required for normal FANCD2 monoubiquitination and full
suppression of SCE
To study whether the DNA binding activity of MHF is required for its function in vivo, we
generated three MHF1 point mutants by substituting 2 clusters of conserved positively charged
amino acid residues with alanine: mutant A (K73A/R74A), B (R87A/R88A), and AB (K73A/
R74A/R87A/R88A) (Figure 6D). Mutagenesis of similar residues in other histone-fold proteins
can disrupt protein-DNA interactions (Hori et al., 2008). We co-expressed these mutants with
MHF2 in E.coli, and found that only mutant A can be co-purified with MHF2 in a stable
complex (Figure 6E and data not shown). Notably, the recombinant complex containing mutant
A lacked dsDNA binding activity (Figure 6F), and also failed to recruit FANCM to fork DNA
(Figure 6G, compare lanes 4 and 6), indicating that MHF requires its DNA binding activity to
recruit FANCM to DNA. Co-IP analyses in HEK293 cells showed that mutant A retained
normal association with MHF2 and FANCM (Figure 6H). Importantly, MHF1-/- DT40 cells
stably expressing mutant A had a lower level of monoubiquitinated FANCD2 (Figure 6A, lanes
3-4), and a higher SCE frequency (Figure 6C) than cells transfected with wildtype MHF1,
suggesting that the DNA binding activity of MHF is required for normal FANCD2
monoubiquitination and full suppression of SCE. Compared to MHF1-/- null cells, the mutant
A-expressing MHF1-/- cells reproducibly exhibited a higher level of monoubiquitinated
FANCD2 and a lower SCE frequency (Figure 6A, lanes 2 and 4; 6C), indicating that this mutant
remains partially functional even though it lacks the ability to bind DNA. This partial function
might be due to the ability of mutant A to stabilize FANCM and MHF2, as the latter two
proteins were recovered to levels higher than not only those of MHF1-/- null cells, but also
those of wildtype cells (Figure 6A, lanes 1, 2 and 4). The findings that mutant A-complemented
cells had a higher than normal amount of FANCM but still exhibited abnormal FANCD2
monoubiquitination and SCE frequency suggest that the stabilization and over expression of
FANCM cannot substitute the function of MHF in vivo.
The interaction between MHF and FANCM is essential for FANCM stability
We also analyzed MHF1 mutant B and AB using the same assays. These mutants cannot be
co-purified with MHF2 in a stable complex from E.coli (data not shown), indicating that
protein-interactions between MHF1-MHF2 were impaired. Consistent with such an
impairment, co-IP in HEK293 cells showed that mutant B was partially defective in association
with MHF2 and FANCM, whereas mutant AB was completely deficient (Figure 6H). Notably,
the levels of FANCM and MHF2 in the mutant B-complemented MHF1-/- DT40 cells were
restored to near those of cells expressing wildtype MHF1 or mutant A (Figure 6A). This is in
contrast to mutant AB-complemented MHF1-/- cells, in which the levels of FANCM and MHF2
were not restored and similar to those of MHF1-/- null cells, suggesting that the stability of
these two proteins strongly depends on their interactions with MHF1.
The levels of monoubiquitinated FANCD2 and SCE in mutant B-complemented MHF1-/- cells
were found to be intermediate between MHF1-/- null cells and those expressing wildtype MHF1
(Figure 6A and C). In contrast, the levels in the mutant AB-complemented MHF1-/- cells were
indistinguishable to those of the MHF1-/- null cells. The degree of defects in FANCD2
monoubiquitination and SCE by the two mutants appears to correlate with their ability to
Yan et al. Page 8













stabilize FANCM. Together with the data of mutant A, the results suggest that MHF has two
important activities: binding to DNA and stabilizing FANCM by protein-protein interactions.
Only when both activities are inactivated (as in mutant AB), MHF completely loses its ability
to promote FANCD2 monoubiquitination and suppress SCEs.
Budding yeast MHF and FANCM orthologs work in the same pathway in resistance to MMS-
induced DNA damage
We investigated whether yeast orthologs of MHF (Figure S2C and D) and FANCM work
together in DNA repair like their vertebrate counterparts. We disrupted budding yeast orthologs
of MHF1 and MHF2 in a srs2 mutant background, and found that both mutants displayed
hypersensitivity to MMS (Figure 7A, middle panels, compare mhfΔ srs2Δ doubles with
srs2Δ single mutant). This feature resembles that of a mph1Δ mutant, which was previously
shown to have MMS hypersensitivity in combination with a srs2Δ mutant (Banerjee et al.,
2008) (Figure 7A). The mhf1Δ mph1Δ or mhf2Δ mph1Δ double mutants displayed MMS
hypersensitivity similar to that of the mph1Δ single mutant in the srs2Δ background (Figure
7A, bottom panels). Furthermore, the survival frequencies of the triple mutant strains at
multiple MMS concentrations were statistically indistinguishable from srs2Δ mph1Δ (Figure
7B). Collectively, these results indicate that both MHF proteins are epistatic with Mph1 in
tolerating MMS-induced DNA damage. In addition, a mhf1Δmhf2Δ double mutant exhibited
MMS hypersensitivity indistinguishable from each mhfΔ single mutant in the srs2Δ
background (Figure 7A, middle panels), consistent with the evidence in mammalian cells that
the two proteins work in the same complex. The MMS resistance of the mhf1Δ or mhf2Δ mutant
is weaker than that of the mph1Δ mutant, reminiscent of results in DT40 cells where the SCE
level of the MHF1-/- mutant is lower than that of the FANCM-/- mutant (Figure 6C). FANCM
or MPH1 may therefore be partially functional without MHF. Taken together, these data
support the findings in mammalian cells and indicate that the MHF proteins play an
evolutionarily conserved role--cooperating with MPH1/FANCM to protect genome integrity.
MHF2 and FANCM act in the same pathway to promote gene conversion at stalled replication
forks in fission yeast
The FANCM ortholog in S. pombe, Fml1, promotes Rad51-dependent gene conversion at
blocked replication forks (Sun et al., 2008). To investigate if MHF is also required, we deleted
the mhf2 gene and assessed what impact this had on the frequency of Ade+ recombinants
induced by a polar replication fork barrier (RTS1) positioned between a direct repeat of
ade6- heteroalleles on chromosome 3 of S. pombe (Figure 7C). This region is replicated
unidirectionally, and consequently only orientation 2 of RTS1 blocks replication between the
repeats. The block of replication results in a strong induction of Ade+ recombinants, which
arise both from Rad51-dependent gene conversion, and Rad51-dependent and independent
deletions (Sun et al., 2008). A His3+ gene positioned between the repeats enables these two
types of recombinants to be distinguished: Ade+His3+ are conversion-types, whereas
Ade+His3- are deletion-types. In a mhf2Δ mutant, the frequency of conversion-types in the
absence of replication fork blockage at RTS1 (i.e. when RTS1 is in orientation 1) is not
significantly different from wild-type (data not shown). However, when RTS1 is in orientation
2 and replication forks are blocked, the frequency of conversion-types is reduced
approximately two-fold in a mhf2Δ mutant compared to wild-type (Figure 7D, left panel). This
reduction is statistically significant (P = <0.0001), but is less than with the fml1Δ mutant, which
shows a 7-fold reduction. Possibly, Fml1 retains some ability to promote gene conversion
without MHF. Importantly the frequency of conversion-types in a fml1Δ mhf2Δ double mutant
is the same as in a fml1Δ single mutant, indicating that Mhf2 acts in the same pathway to
promote gene conversion at blocked replication forks as Fml1 does.
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Intriguingly, the loss of conversion-types in the mhf2Δ mutant is accompanied by an
approximately two-fold increase in deletion-types (Figure 7D, right panel), which again is
statistically significant (P = <0.0001). This increase is dependent on Fml1 as it is suppressed
in a fml1Δ mhf2Δ double mutant (P = <0.01). These data suggest that MHF may act to prevent
Fml1 mediated Rad51-dependent strand invasion events from giving rise to deletions.
DISCUSSION
A network of DNA caretaker proteins keeps replication forks under surveillance to prevent
gross chromosomal rearrangements in S phase. Here we have identified a conserved DNA
remodeling complex that protects replication forks in eukaryotes. This complex contains
FANCM, a branched DNA binding and remodeling enzyme, as well as two histone fold
proteins, MHF1 and MHF2. In vertebrates, MHF1 and MHF2 are bona fide components of the
FA core complex, and are required for normal activation of the FA pathway, including optimal
monoubiquitination of the FANCI-FANCD2 complex in response to DNA damage, cellular
resistance to DNA crosslinking drugs, and prevention of chromosomal breakage. MHF and
FANCM also constitute a FANC-independent complex, FANCM-MHF, which is rapidly
recruited to blocked forks in vivo. Our genetic analyses in yeast suggest that FANCM-MHF
is a conserved complex that promotes gene conversion at blocked replication forks, in contrast
to the FA core complex, which exists only in vertebrates (Figure 7E).
MHF is a histone fold complex that functions in DNA damage response and at centromeres
Histone fold proteins can facilitate transcription (TAF octamer in TFIID), chromatin-
remodeling (Chrac14/Chrac16 in the CHRAC complex), and stabilization of centromeres
(CENP-T/CENP-W). Our finding that MHF functions with FANCM extends the participation
of histone-fold complexes to the DNA damage response. While our manuscript was under
review, Amano and colleagues described a CENP-S complex that is identical to MHF, with
MHF1 and MHF2 being CENP-S and CENP-X, respectively (Amano et al., 2009). They
showed that this complex is essential for the stable assembly of kinetochore structure and
normal mitosis. Centromeric DNA is intrinsically difficult to replicate and rich in replication
pause sites. MHF may target FANCM at centromeres to forestall the disastrous encounter of
replication forks with secondary DNA structures and/or tightly DNA bound protein complexes.
FANCM and MHF constitute a conserved DNA remodeling complex
MHF1 and MHF2 have yeast orthologs that are genetically epistatic with the FANCM
orthologs in resistance to MMS and promotion of gene conversion at stalled forks. This leads
us to propose that FANCM and the two MHF proteins constitute a core complex that remodels
DNA structure in yeast and higher eukaryotes. In accord with this hypothesis, human MHF
and FANCM can be co-immunoprecipitated as a complex that is largely free of the other FA
core complex components. The FANCM-MHF complex can be reconstituted by baculovirus-
expressed proteins, and the resulting complex possesses DNA binding and fork-reversal
activities stronger than FANCM alone. Both FANCM and MHF are rapidly recruited to ICLs
specifically in S phase, and the recruitment of MHF1 to ICLs is stimulated by DNA replication.
Moreover, depletion of either FANCM or MHF in HeLa cells results in cellular sensitivity to
DNA crosslinking drugs, which blocks progression of replication forks. Furthermore, FML1
and MHF mutants in S. pombe are defective in promoting gene conversion at replication fork
barriers. These findings suggest that FANCM-MHF may stabilize and remodel blocked
replication forks to facilitate DNA damage signaling and repair.
How might MHF contribute to the remodeling activity of FANCM-MHF? MHF may anchor
the complex to DNA damage sites in chromatin. Consistent with this, MHF can bind in vitro
assembled chromatin template and its depletion reduces the level of FANCM in the chromatin
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fraction and abrogates recruitment of FANCM to laser-induced ICLs. A MHF point mutant
unable to bind dsDNA is defective in recruiting FANCM to DNA in vitro, and fails to promote
normal FANCD2 monoubiquitination and fully suppress SCE in DT40 cells. Our biochemical
studies suggest that at stalled forks, FANCM most likely binds the DNA branch point of
replication intermediates (Gari et al., 2008b; Xue et al., 2008), whereas MHF would associate
with surrounding dsDNA. Binding of MHF to dsDNA may help to recruit and orient FANCM
at the branch point. In the FA core complex, FAAP24 may further facilitate this process by
anchoring FANCM to the surrounding ssDNA region of stalled forks. After FANCM is
recruited to stalled forks, MHF may facilitate repair or bypass of the stalled forks by stimulating
fork reversal activity of FANCM. This stimulation may be independent of the role of MHF in
FANCD2 monoubiquitination, which has been shown not to require remodeling activity of
FANCM (Rosado et al., 2009; Singh et al., 2009; Xue et al., 2008).
In a cellular context, MHF may play an additional role in stabilizing FANCM via protein-
protein interactions. This was revealed because the MHF mutant A is only partially defective
in FANCD2 monoubiquitination and SCE suppression despite inactivation of its DNA binding
activity. We found a strong correlation between FANCM stability and its ability to associate
with various MHF point mutants. MHF mutant A has normal association with FANCM and
can fully stabilize FANCM as the wildtype protein. Mutant B has reduced association with
FANCM and cannot restore FANCM to the level by the wildtype protein. Mutant AB is
completely defective in FANCM association so that it fails to stabilize FANCM. Notably,
mutant AB which lacks both DNA binding activity and FANCM association is completely
deficient in promoting normal FANCD2 monoubiquitination and suppressing SCE. These data
suggest that MHF requires both DNA-binding and FANCM association to function in vivo.
FANCM-MHF and FA core complex may have independent functions
In vertebrates, MHF also plays a signaling role as part of the FA core complex, as its depletion
or inactivation of its DNA binding activity reduces FANCD2 monoubiquitination in response
to DNA damage. A recent report shows that FANCD2 monoubiquitination in vitro requires
only FANCL but not other subunits of the FA core complex (Alpi et al., 2008), suggesting that
the role of MHF in this reaction is indirect. A previous study suggested that the DNA binding
activity of FANCM is required for FANCD2 monoubiquitination (Xue et al., 2008), possibly
by anchoring FA core complex to chromatin (Kim et al., 2008). Our findings that MHF
stabilizes FANCM and cooperates with FANCM to bind DNA suggest that MHF indirectly
contributes to this process by stimulating recruitment of FANCM and associated FA core
complex to chromatin.
In addition to their differential roles in FANCD2 monoubiquitination, FA core complex and
FANCM-MHF appear to have other independent functions. For example, HeLa cells lacking
MHF or FANCM display MMS and camptothecin hypersensitivity, a cellular feature absent
in human cells deficient of other FA core complex components. Moreover, FANCM and MHF
are epistatic in suppression of SCEs in DT40 cells, whereas FANCM and FANCC are not
(Rosado et al., 2009).
In vertebrates, FANCM-MHF associates with not only components of the FA core complex,
but also subunits of the BLM complex (BLM, Topo IIIa, RMI and RPA). FANCM and BLM
suppress SCE through the same pathway in DT40 cells (Rosado et al., 2009). These results
reinforce our earlier findings that FANC and BLM complexes work together in the BRAFT
super-complex to protect genome integrity (Wang, 2007). Elucidation of the structure and
function of this large complex should shed new light on the mechanism of replication fork
surveillance.
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Gel filtration, immunoprecipitation and protein identification
Superose 6 gel filtration and immunoprecipitation were performed as described (Ciccia et al.,
2007). The eluted immunoprecipitates were resolved by 8-16%Tris-Glycine gel (InVitrogen),
visualized by silver-staining, and were subjected to mass spectrometry analyses.
Fork regression assay
The plasmid-based replication fork reversal assay was described in (Gari et al., 2008a).
Protein Recruitment to laser-induced localized ICLs
We followed the previous protocol to detect proteins recruited at laser-induced localized ICLs
(Thazhathveetil et al., 2007).
Detecting proteins recruited to a site-specific psoralen-ICL by eChIP
The eChIP was carried out as described (Shen et al., 2009).
Budding yeast strains and MMS sensitivity assay
We followed the previous protocols used for Mph1 study to generate Mhf mutants and
performed MMS sensitivity assay (Banerjee et al., 2008).
S. pombe strains and recombination assay
Strain construction and the direct repeat recombination assay has followed published protocols
(Sun et al., 2008).
Detailed Experimental materials and methods can be found in Supplemental Information.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Identification of MHF1 and MHF2 as integral components of the FA core complex
(A) Immunoblotting showing Superose 6 gel-filtration profiles of FANCM, MHF1 and MHF2
in HeLa nuclear extract. The peak fractions and those corresponding to marker proteins are
indicated at the bottom. (B) A silver-stained gel showing that the complex purified by a
FANCM antibody from the pooled peak 1 fractions in (A) contained MHF1, MHF2 and other
components of FA core and BLM complexes. IP indicates immunoprecipitation. (C)
Immunoblotting shows that MHF1, MHF2 and other FA core complex components were
present in the immunoprecipitates isolated from peak 1 fractions by MHF1, FANCM or
FANCA antibodies. Nuclear extract (NE) was used as a loading control. (D) As described in
(B), except a MHF1 antibody was used in IP. (E) Immunoblotting shows that MHF2 co-
immunoprecipitated with MHF1 and other FA core complex components from HeLa cells
stably expressing Flag-tagged MHF2, but not from control HeLa cells. A Flag antibody was
used in IP. (F) As described in (B), except that peak 2 fractions in (A) were used for IP by a
MHF1 antibody. (see also Figures S1 and S2).
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Figure 2. MHF binds double-strand and branch-structured DNAs, but not single-strand DNA
(A) Coomassie blue-stained SDS-PAGE gels showing HIS-tagged recombinant proteins
MHF1, MHF2 and MHF complex purified from E.coli. A nonspecific band was marked with
“x”. (B) Electrophoretic mobility shift assay (EMSA) for testing DNA binding activity of
MHF1, MHF2 and MHF complex. A variety of DNA substrates (0.5nM) illustrated at the top
were incubated with 0.6 μM MHF1, 0.6 μM MHF2 and increasing amounts (0.3 and 0.6μM)
of MHF complex, respectively. Asterisks denote 32P label at the DNA 5’ end. The arrows
indicate the shift bands of MHF-DNA complex. The dots represent free DNA probe. (see also
Figure S3).
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Figure 3. MHF stimulates DNA binding and fork reversal activities of FANCM
(A) A silver-stained gel showing FANCM-MHF complex immunoprecipitated directly by a
MHF1 antibody from HeLa nuclear extract (NE). Three major polypeptides were identified as
FANCM, MHF1 and MHF2 by mass spectrometric analyses. (B) A diagram shows the mapping
of MHF-interaction domain within FANCM. Left panels show FLAG-tagged wild type and
various deletion mutants of FANCM used in Figure S4D. Right panels show the presence or
absence of interactions between various FANCM constructs and MHF. (C) EMSA showing
the DNA binding activity of MHF and FANCM754. The reaction contained the DNA substrate
(0.5nM) with or without recombinant FANCM754 protein or MHF complex as indicated. The
protein concentrations are: FANCM754: 22.5, 45 and 90 nM in lanes 2 to 4 and 6 to 8,
respectively; MHF: 300 nM in lanes 5 to 8; FANCM754: 15nM in lanes 10, 14, 15, 16, 18, 22,
23, 24, 26, 30, 31, 32; MHF: 50, 100 and 150nM in lanes 11 to 13, 14 to 16, 19 to 21, 22 to
24, 27 to 29, and 30 to 32, respectively. The shifted bands of indicated protein-DNA complex
and free DNA probe are illustrated. (D) A silver-stained gel showing Flag-FANCM purified
from baculovirs-infected insect cells (Sf21), either alone or in association with the MHF
complex (left panels). At these protein concentrations, MHF proteins were hardly detectable
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by silver- staining due to their low molecular mass. Western blots confirmed that MHF1 and
MHF2 were co-immunoprecipitated with Flag-FANCM (right panels). (E) Comparison of the
DNA binding activity of purified FANCM and FANCM-MHF complex on fork DNA substrate
by EMSA. 5’-32P-labeled synthetic replication forks (0.5 nM) were incubated for 30 min at
room temperature with increasing concentrations of FANCM or FANCM-MHF (0, 0.125, 0.25,
0.5, 1, 2, 4, 6, 8, 10 nM). MHF does not bind this substrate at 10nM. (F) Experimental scheme.
Fork reversal converts the replication fork into a four-way junction (b). Complete fork reversal
dismantles the joint molecules into nicked circular and labeled linear duplex (c). (G) Increasing
concentrations of Flag-FANCM or Flag-FANCM-MHF (0, 0.125, 0.25, 0.5, 1, 2, 4, 6, 8, 10
nM) were incubated with the replication fork substrate (0.5 nM) for one hour at 37°C. The
different labeled species are (top down) the four-way junction intermediate (b), the original
replication fork substrate (a), and the linear duplex end product of fork reversal (c). (H) Product
formation shown in (G) was quantified by PhosphorImaging and expressed as percentage of
total DNA. (see also Figure S4).
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Figure 4. MHF is required for stability of FANCM, activation of the FA pathway and cellular
resistance to DNA damaging agents
(A and B) Immunoblotting shows that depletion of MHF1 or MHF2 reduces the level of
FANCM in whole cell lysates (A) and chromatin fractions (B) of HeLa cells. Nontargeting
siRNA oligos were used as a control. α-Tubulin, Histone H3 and Actin were included as loading
controls. (C and D) Immunoblotting shows that HeLa cells depleted of MHF1 (C) or MHF2
(D) have reduced levels of monoubiquitinated FANCD2 and FANCI in the presence of MMC
(60 ng/ml) or cisplatin (5 μM)(Cis). “L” (long) and “S” (short) represent ubiquitinated and
non-ubiquitinated forms, respectively. The ratio between long and short forms was obtained
by using KODAK Molecular Imaging Software and shown below the blots. (E, F and G)
Clonogenic survival assays of HeLa cells depleted of MHF1, MHF2 or FANCM by siRNA
following the treatment with MMC, MMS or CPT at the indicated concentrations. Three
independent experiments were performed. The results were reproducible, and a representative
data of mean surviving percentage with S.E.M. from triplicate cultures are shown. (see also
Figure S5).
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Figure 5. MHF is rapidly recruited to ICL sites in S phage cells and required for FANCM
recruitment
(A) Images showing that MHF1 and FANCM were recruited to psoralen-induced ICLs
beginning 15 mins after laser photoactivation in S phase cells. The yellow arrow indicates the
position of the laser-targeted region. (B) Images showing that HeLa cells depleted of MHF1
or MHF2 by siRNA have deficient recruitment of FANCM to psoralen-induced ICLs.
Nontargeting siRNA oligos and γ-H2AX were used as controls. Images represent 15 mins post
treatment time point. The recruitment of FANCM and γ-H2AX to ICL sites was indicated by
yellow and white arrows, respectively. (C) Graph showing the percentages of cells in which
FANCM was recruited to psoralen-induced ICLs at various time points after photoactivation.
No recruitment of FANCM to ICLs was observed in MHF2-depleted cells at 30 mins post
treatment. HeLa cells were either transfected with siRNA against MHF1, MHF2 or control
siRNA and synchronized in S phase prior to the experiment. Values are averages from two
independent experiments with error bars representing standard error of the mean. (D)
Schematic representation of the plasmid substrates used in the eCHIP assay. The presence of
psoralen-ICL is indicated. Cells expressing EBNA (+) support replication of the plasmid,
whereas those lacking it (-) do not. (E) Recruitment of MHF1 to the site of ICL was detected
by eChIP. The enrichment of MHF1 and FAAP24 at the ICL in replicating (293EBNA) and
nonreplicating (HEK293) DNA substrates was reflected by their relative recruitment ratio
compared to the control substrate without ICL. The relative recruitment was derived by
normalizing the comparative concentration (from real-time PCR) of crosslinked substrate to
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that of the unmodified control substrate. Error bars represent standard deviation from three
independent experiments. (see also Figure S6).
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Figure 6. MHF and FANCM act in the same pathway for FANCD2 monoubiquitination and
suppression of SCE in chicken DT40 Cells
(A) Immunoblotting shows levels of FANCD2, FANCM, and MHF2 in whole cell lysates from
various DT40 cells (wildtype (WT), MHF1-/- cells, and MHF1-/- cells complemented with
human wildtype (wt) or mutant MHF1 as described in (D)). The ratio between the
monoubiquitinated and unubiquitinated FANCD2 (L/S) was shown. Cells were treated with
MMC (50 ng/ml) for 18 hr. BAF57 was used as a loading control. (B) Immunoblotting shows
levels of monoubiquitinated and unubiquitinated FANCD2 in whole cell lysates from various
DT40 cells as indicated on the top. (C) Histograms showing spontaneous SCE levels of various
DT40 cells as indicated within each graph. MHF1-/- cells transfected with human MHF1
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wildtype (wt) or mutants (described in D) were also shown. The mean number of SCEs per
metaphase is listed. (D) Illustration of three human MHF1 point mutants generated by
substituting 2 clusters of positively-charged amino acid residues (KR and RR) to alanine as
indicated. (E) A Coomassie blue-stained SDS-PAGE gel shows the purified recombinant MHF
complex containing MHF1 of either wildtype (wt) or mutant A (mut A). (F) Comparison of
the DNA binding activity of MHF complexes containing either wildtype or mutant A of MHF1
by EMSA. Reactions contain 32P-labeled dsDNA substrate (0.5nM) and 0.3 or 0.6μM of the
MHF complex as indicated. (G) Comparison of the DNA binding activity of FANCM754 with
either wildtype (wt) or mutant A MHF by EMSA. The reaction contained the 32P-labeled fork
DNA substrate (0.5nM) with or without FANCM754 protein or MHF complex (wt or mut A).
The protein concentrations are: FANCM754: 22.5nM (lanes 2, 4 and 6); MHF: 450 nM (lanes
3 and 5) and 300 nM (lanes 4 and 6). (H) IP-Western analyses show association between
FANCM and various Flag-tagged MHF1 point mutants in HEK293 cells. (see also Figure S7).
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Figure 7. Yeast MHF and FANCM orthologs work in the same pathway to resist MMS-induced
DNA damage and promote gene conversion at stalled replication forks
(A) Qualitative spot tests for strain sensitivities to MMS reveal a common role and shared
pathway for Mph1, Mhf1, and Mhf2 in DNA damage resistance. (B) Quantitative analysis of
MMS sensitivities shows that the triple mutants are not statistically distinguishable from
srs2Δ mph1Δ at two different MMS concentrations. P values for the mhf1Δ and mhf2Δ triple
mutants, respectively, versus srs2Δ mph1Δ are as follows: 0.35, 0.23 (0.01% MMS); 0.36, 0.97
(0.1% MMS). (C) Schematic showing the direct repeat recombination substrate on
chromosome 3 of S. pombe plus the two types of Ade+ recombinants (Sun et al., 2008). (D)
Ade+ recombinant frequencies for various strains as indicated. Error bars are the standard
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deviations. (E) A model describes common and unique functions of FANCM-MHF and FA
core complex in signaling and repairing of blocked replication forks. The former acts in yeast,
invertebrates and vertebrates, whereas the latter functions only in vertebrates. While both
complexes can promote reversal of blocked forks (indicated by the red brick) to allow
subsequent repair, only the FA core complex has a signaling role in monoubiquitinating
FANCD2 and FANCI.
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